FDA Cites Babikian Healthcare Products CJSC in 2026-09-21 Warning Letter — CGMP/Finished Pharmaceuticals/Adulterated
Letter issued · posted to fda.gov .
Subject as published: CGMP/Finished Pharmaceuticals/Adulterated
TL;DR
Here's the summary: The FDA Center for Drug Evaluation and Research issued a warning letter (Reference 320-26-128) to Babikian Healthcare Products CJSC on September 21, 2026, citing significant Current Good Manufacturing Practice (CGMP) violations at the facility (FEI 3027526825) in Armenia. The violations include: failure to test component identity and validate supplier test results; failure to conduct adequate finished product testing for identity, strength, and microbiological quality prior to release; and failure of the quality control unit to exercise appropriate oversight—resulting in the determination that finished OTC drug products are adulterated under the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 351(a)(2)(B)). The letter states that failure to adequately address these violations may result in regulatory action without further notice.
Argus analysis
# FDA Warning Letter Analysis: Babikian Healthcare Products CJSC
**Company and Findings**
Babikian Healthcare Products CJSC, an Armenian manufacturer of over-the-counter drugs destined for the US market, received a warning letter from FDA's Center for Drug Evaluation and Research on September 21, 2026. The inspection centered on Current Good Manufacturing Practice (CGMP) violations identified during FDA's review of records submitted under section 704(a)(4) of the Federal Food, Drug, and Cosmetic Act. FDA determined that the company's manufacturing methods, facilities, and controls do not conform to CGMP standards, rendering finished drug products adulterated under federal law.
**Regulatory Citations and Implications**
The violations cite three primary areas of 21 CFR parts 210 and 211. First, 21 CFR 211.84(d) requires manufacturers to test incoming components for identity and validate supplier test data at regular intervals—the company accepted supplier certificates without independent verification. Second, 21 CFR 211.165(a) and 211.165(b) mandate finished-product testing for active ingredient identity, strength, and microbial content prior to release; Babikian's records lacked adequate assay and microbiological testing documentation. Third, 21 CFR 211.22 obligates quality units to oversee CGMP compliance, including establishing manufacturing procedures, maintaining batch records, and providing stability data for expiration dating. These sections form the foundation of pharmaceutical quality assurance under US law.
**Next Steps and Industry Watch Points**
Babikian has fifteen days to submit a written response to FDA. Products from the facility remain under Import Alert 66-40, issued June 22, 2026, blocking entry into the US. FDA recommends engaging a CGMP consultant under 21 CFR 211.34 to conduct a six-system audit and remediation plan. Compliance officers should monitor whether the company submits evidence of corrective actions, independent testing protocols, and quality system restructuring. FDA may conduct follow-up inspections and will likely refuse new drug application approvals until violations are fully resolved and verified.
Severity context
High severity. Typically QSR / device CGMP, adulterated-drug, or significant labeling matters — usually drives a documented corrective and preventive action (CAPA) program.
Regulatory background
CGMP citations typically reference 21 CFR Part 211 (drugs) or 21 CFR Part 600 (biologics). Common subjects include identity testing of incoming components (211.84), validated cleaning procedures (211.67), and stability program design (211.166).
What peer compliance teams typically do next
Most compliance officers at peer companies use a Warning Letter against a named entity as a checklist for their own CAPA program. Common steps: pull the verbatim FDA letter; map each cited 21 CFR section against the team’s SOP library; confirm CAPA coverage; brief the QMR (Quality Management Review) on whether the cited subject matter is in scope for the next internal audit. The 15-business-day response window applies to the cited entity, not to peers — but a documented internal review against the cited subjects is what regulators expect to see if a peer is later inspected on the same topic.
Excerpt from the FDA Warning Letter (public domain, 17 USC §105)
WARNING LETTER Babikian Healthcare Products CJSC MARCS-CMS 730513 — September 21, 2026 More Warning Letters Warning Letters About Warning and Close-Out Letters Delivery Method: VIA ELECTRONIC MAIL READ/DELIVERY RECEIPT REQUESTED Reference #: 320-26-128 Product: Drugs Over-the-Counter Drugs Recipient: Recipient Name Dr. Dikran Babikian Recipient Title Chief Executive Officer Babikian Healthcare Products CJSC Gevorg Chaush Highway 90 2413 Proshyan Community Kotayk Armenia (b)(4) Issuing Office: Center for Drug Evaluation and Research (CDER) United States September 21, 2026 WARNING LETTER Reference number: 320-26-128 To Dr. Dikran Babikian: This warning letter advises you of significant violations identified during a U.S. Food and Drug Administration (FDA) review of records submitted from your facility. Promptly address the violations described herein without delay, including ensuring that appropriate resources are allocated to fully address the violations and prevent their recurrence. This is not intended to be an all-inclusive list of the violations that exist at your facility. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations. Failure to adequately address violations may result in regulatory action without further notice. FDA Review Violations were identified and documented during review of your drug manufacturing facility, Babikian Healthcare Products CJSC, FDA Establishment Identifier (FEI) 3027526825. 1 This review was conducted under FDA’s statutory authority and public health responsibilities to protect the public from unsafe, ineffective, and poor quality drugs. Your facility is registered with the FDA as a manufacturer of over-the-counter (OTC) drug products. FDA has reviewed the records you submitted in response to our August 12, 2025 request for records and other information pursuant to section 704(a)(4) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) for your facility. This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations, parts 210 and 211 (21 CFR, parts 210 and 211). Because your methods, facilities, or controls for manufacturing, processing, packing, or holding of drugs as described in your response to our 704(a)(4) request do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. 351(a)(2)(B)). Violations of the Federal Food, Drug, and Cosmetic Act The following are violations identified during our review. As a reminder, this is not an all-inclusive list of violations at your facility. 1. Your firm failed to conduct at least one test to verify the identity of each component of a drug product. Your firm also failed to validate and establish the reliability of your component supplier’s test analyses at appropriate interv…
Excerpt only. The full verbatim Warning Letter is the source of truth — always read the original before regulatory decisions.
The verbatim FDA Warning Letter is the source of truth. Always read the original before acting on any analysis or summary on this page.
Read the full letter on fda.gov ↗Frequently asked questions
- Is the FDA warning letter to Babikian Healthcare Products CJSC publicly available?
- Yes. The full verbatim letter is published at fda.gov. Argus HQ links directly to the source: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/babikian-healthcare-products-cjsc-730513-09212026.
- What does a "high" severity rating mean for this letter?
- High severity. Typically QSR / device CGMP, adulterated-drug, or significant labeling matters — usually drives a documented corrective and preventive action (CAPA) program.
- What is the regulatory background for a CGMP — Current Good Manufacturing Practice warning letter?
- CGMP citations typically reference 21 CFR Part 211 (drugs) or 21 CFR Part 600 (biologics). Common subjects include identity testing of incoming components (211.84), validated cleaning procedures (211.67), and stability program design (211.166).
- What is the standard FDA response window for a warning letter?
- FDA warning letters typically require a written response within 15 working days of receipt, outlining the corrective and preventive actions the company will take.
argus.hq
Don’t find out about the next one six weeks late.
Argus reads every FDA Warning Letter the day it publishes, summarizes it against your watchlist, and lands the ones touching your business in your inbox at 6am ET. Plans from $99/month. Cancel any time.
methodology
The analysis above is produced by Anthropic Claude Haiku 4.5 against the verbatim FDA Warning Letter excerpt and is brand-voice lint-checked before publish. The TL;DR is the same summary that ships in the customer email digest. Severity is auto-classified by Argus from the subject string and letter body using rules documented in lib/ingestion/fda-warning-letters.ts.
Argus HQ is informational only. Summaries and analyses are AI-generated and may contain errors, misclassifications, or omissions. Verify against the FDA source URL above. Argus HQ is not a law firm, accounting firm, or regulatory agency, and provides no legal, accounting, financial, medical, or regulatory advice.
Compiled by Argus HQ Research from FDA primary sources · Reviewed by Andy Gaber, Founder
Cite this record
Reusing this data in reporting or research? Here’s a ready-made citation.
Argus HQ Research (2026). FDA Cites Babikian Healthcare Products CJSC in 2026-09-21 Warning Letter — CGMP/Finished Pharmaceuticals/Adulterated. Digital Empire Holdings LLC. Retrieved from https://argushq.ai/fda/warning-letter/fda-wl-babikian-healthcare-products-cjsc-2026-09-21-cgmp
"FDA Cites Babikian Healthcare Products CJSC in 2026-09-21 Warning Letter — CGMP/Finished Pharmaceuticals/Adulterated." Argus HQ Research, Digital Empire Holdings LLC, 2026, argushq.ai/fda/warning-letter/fda-wl-babikian-healthcare-products-cjsc-2026-09-21-cgmp.
Argus HQ Research. "FDA Cites Babikian Healthcare Products CJSC in 2026-09-21 Warning Letter — CGMP/Finished Pharmaceuticals/Adulterated." Digital Empire Holdings LLC. Accessed September 30, 2026. https://argushq.ai/fda/warning-letter/fda-wl-babikian-healthcare-products-cjsc-2026-09-21-cgmp.
@misc{argushq_argushq_ai_fda_warning_letter_fda_wl_babikian_healthcare_products_cjsc_2026_09_21_cgmp_2026,
title = {FDA Cites Babikian Healthcare Products CJSC in 2026-09-21 Warning Letter — CGMP/Finished Pharmaceuticals/Adulterated},
author = {{Argus HQ Research}},
year = {2026},
publisher = {Digital Empire Holdings LLC},
url = {https://argushq.ai/fda/warning-letter/fda-wl-babikian-healthcare-products-cjsc-2026-09-21-cgmp},
note = {Accessed: September 30, 2026}
}